Incannex Healthcare Inc.
IXHL
Last
$3.10
Day
-3.1%
1y
-74.6%
5y
-99.8%
52w
-78.5%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-1334d
EMA 21
3.29
EMA 50
3.34
EMA 200
6.22
20d high
-16.7%
5y high
-100.0%
5y range
0th
Positions held
Your positionsIXHL isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-12
Hold
avoid
Signal
Sell
Target
$3.46
Stop
$2.99
Stop distance
3.5%
Target vs last
+11.6%
Fundamentals
| Market cap | $40.14M | Enterprise value | -$27.47M | Trailing P/E | — | Forward P/E | -1.89 |
| PEG | — | Price / book | 0.60 | Beta | 2.82 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -47.8% | ROA | -24.6% | Debt / equity | 0.00 |
| Current ratio | 48.81 | Free cash flow | -$9.25M | Analyst recommendation | strong_buy | Mean target | $18.73 |
| 52w high | $14.91 | 52w low | $2.49 |
Quarterly
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | — | $0.0M |
| Op margin | — | — | — | — | — |
| Net income | -$3.9M | -$6.5M | -$6.4M | — | -$4.0M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$4.0M | -$6.5M | -$6.4M | — | -$4.6M |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | — | $0.0M | $0.0M | $0.0M |
| Op margin | — | -155058.3% | — | — |
| Net income | — | -$18.5M | -$48.8M | -$10.3M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | $0.0M | -$0.0M |
| Operating income | — | -$18.6M | -$13.6M | -$10.2M |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-01 · Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) FY26
2026-09-09 · Incannex Healthcare Provides Corporate Update on Clinical Progress, Intellectual Property and Capital Position
2026-08-25 · Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X
2026-07-23 · Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea
2026-07-15 · Incannex (IXHL) Secures U.S. Patent Grant in Obstructive Sleep Apnea for IHL-42X
Price (daily)
Full chart · RSI · MACD · patternsIXHL · daily-5.7% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin